AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33034357 — intervention group
Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 24
Study 33034357 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 24
Study 33034357 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.5 years group (both SMILE and LASIK)
Number of subjects: 24
Study 33034357 — intervention group
Group type: EXPERIMENTAL
Intervention: High myopic treatment with LASIK
Number of subjects: 24
Study 33034357 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry eye parameters
Number of subjects: 24
Study 36451496 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural-general anesthesia
Number of subjects: 347
Study 36451496 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 347
Study 36451496 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 347
Study 33829717 — intervention group
Group type: EXPERIMENTAL
Intervention: Thulium laser
Number of subjects: 76
Study 33829717 — intervention group
Group type: COMPARATOR
Intervention: Stapler
Number of subjects: 76
Study 33761459 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) 420 J
Number of subjects: 15
Study 33761459 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 15
Study 33761459 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 15
Study 32163837 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI
Number of subjects: 0
Study 32163837 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 32163837 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33684015 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (upper limb fascial therapy, 50 min weekly session for three weeks)
Number of subjects: 69
Study 33684015 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 69
Study 33813850 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP target of <120 mm Hg
Number of subjects: 9361
Study 33813850 — intervention group
Group type: COMPARATOR
Intervention: Systolic BP target of <140 mm Hg
Number of subjects: 9361
Study 33813850 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive BP treatment
Number of subjects: 9361
Study 33765667 — intervention group
Group type: EXPERIMENTAL
Intervention: SnF2 dentifrice B (0.454% SnF2 + sodium hexametaphosphate)
Number of subjects: 32
Study 33765667 — intervention group
Group type: EXPERIMENTAL
Intervention: SnF2 dentifrice C (0.454% SnF2 + citrate)
Number of subjects: 32
Study 33765667 — intervention group
Group type: EXPERIMENTAL
Intervention: SnF2 dentifrice D (experimental 0.454% SnF2 with increased bioavailable Sn)
Number of subjects: 32
Study 33765667 — intervention group
Group type: EXPERIMENTAL
Intervention: SnF2 dentifrice E (0.454% SnF2 + 0.078% NaF + sodium hexametaphosphate)
Number of subjects: 32
Study 33765667 — intervention group
Group type: EXPERIMENTAL
Intervention: SnF2 dentifrice F (0.454% SnF2 + 0.078% NaF + citrate)
Number of subjects: 32
Study 33765667 — intervention group
Group type: COMPARATOR
Intervention: Negative Control (NC: 0.1% NaF + 0.76% sodium monofluorophosphate)
Number of subjects: 32
Study 33765667 — intervention group
Group type: EXPERIMENTAL
Intervention: Zn/Arg dentifrice (NaF + zinc + arginine)
Number of subjects: 32
Study 32415802 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg daily for 12 weeks
Number of subjects: 36
Study 32415802 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg daily for 12 weeks
Number of subjects: 36
Study 35533200 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of the noradrenaline reuptake inhibitor atomoxetine
Number of subjects: 17
Study 35533200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 34702422 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmanned Aerial Vehicle (UAV) technology
Number of subjects: 47
Study 34702422 — intervention group
Group type: COMPARATOR
Intervention: Standard Practice (SP)
Number of subjects: 47
Study 34546428 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding valves (SE)
Number of subjects: 17295
Study 33131470 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 0
Study 33131470 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 0
Study 33131470 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 0
Study 33131470 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive anti-inflammatory therapy combined with anticoagulation
Number of subjects: 0
Study 34098038 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook social media campaign
Number of subjects: 23
Study 33228562 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention
Number of subjects: 0
Study 33228562 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 616381698 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 0
Study 616381698 — intervention group
Group type: EXPERIMENTAL
Intervention: Major cardiovascular events
Number of subjects: 0
Study 616381698 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial infarction
Number of subjects: 0
Study 616381698 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke
Number of subjects: 0
Study 616381698 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization for heart failure
Number of subjects: 0
Study 616381698 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization for hypoglycemia
Number of subjects: 0
Study 33486130 — intervention group
Group type: EXPERIMENTAL
Intervention: MAST MMPR
Number of subjects: 1561
Study 33486130 — intervention group
Group type: COMPARATOR
Intervention: Original MMPR
Number of subjects: 1561
Study 33486130 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MMPRs
Number of subjects: 1561
Study 36453766 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise session (AAES)
Number of subjects: 32
Study 33284342 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available plasmalike isotonic fluids
Number of subjects: 0
Study 33284342 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35268539 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain intervention (diet, exercise, cognitive training, and vascular/metabolic risk monitoring)
Number of subjects: 1260
Study 35268539 — intervention group
Group type: COMPARATOR
Intervention: Regular health advice (control group)
Number of subjects: 1260
Study 35268539 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain intervention
Number of subjects: 1260
Study 35268539 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Zung score
Number of subjects: 1260
Study 35268539 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in Zung score
Number of subjects: 1260
Study 32886212 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS)
Number of subjects: 459
Study 32886212 — intervention group
Group type: COMPARATOR
Intervention: External-Beam Radiotherapy (EBRT)
Number of subjects: 459
Study 32886212 — intervention group
Group type: COMPARATOR
Intervention: Brachytherapy by Permanent Seed Implantation (PSI)
Number of subjects: 459
Study 32886212 — intervention group
Group type: COMPARATOR
Intervention: Radical Prostatectomy (RP)
Number of subjects: 459
Study 35803757 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg intravenously after induction of anaesthesia
Number of subjects: 1466
Study 35803757 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenously after induction of anaesthesia
Number of subjects: 1466
Study 33128492 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 1% cream
Number of subjects: 30
Study 33128492 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% cream
Number of subjects: 30
Study 33128492 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 30
Study 34819721 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate (RT)
Number of subjects: 260
Study 34819721 — intervention group
Group type: COMPARATOR
Intervention: Etomidate-Propofol (EP)
Number of subjects: 260
Study 34819721 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 260
Study 36377169 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 90
Study 36377169 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 90
Study 35554601 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage plus lifestyle advice
Number of subjects: 74
Study 35554601 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapeutic ultrasound plus lifestyle advice
Number of subjects: 74
Study 33904521 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 105
Study 33904521 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 105
Study 32343642 — intervention group
Group type: EXPERIMENTAL
Intervention: I/T/DIN/GM-CSF (irinotecan, temozolomide, dinutuximab, and GM-CSF)
Number of subjects: 53
Study 32343642 — intervention group
Group type: EXPERIMENTAL
Intervention: I/T/DIN/GM-CSF
Number of subjects: 53
Study 35183878 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus biofeedback
Number of subjects: 24
Study 35183878 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic exercise
Number of subjects: 24
Study 32006758 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients undergoing PCI
Number of subjects: 15957
Study 32006758 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic patients undergoing PCI
Number of subjects: 15957
Study 32006758 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet strategy (experimental versus reference)
Number of subjects: 15957
Study 34864993 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratch prior to the second IVF/ICSI treatment
Number of subjects: 933
Study 34864993 — intervention group
Group type: COMPARATOR
Intervention: No scratch (control group)
Number of subjects: 933
Study 32246489 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontitis
Number of subjects: 826
Study 32246489 — intervention group
Group type: COMPARATOR
Intervention: Normal respiratory function
Number of subjects: 826
Study 36399215 — intervention group
Group type: EXPERIMENTAL
Intervention: KingVision channeled (KVC) blade
Number of subjects: 100
Study 36399215 — intervention group
Group type: COMPARATOR
Intervention: KingVision non-channeled (KVNC) blade
Number of subjects: 100
Study 36399215 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscope (DL)
Number of subjects: 100
Study 34398011 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Number of subjects: 82
Study 34398011 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade
Number of subjects: 82
Study 33261355 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed images (randomized set of neutrally or negatively arousing images)
Number of subjects: 84
Study 33261355 — intervention group
Group type: COMPARATOR
Intervention: Pure images (organized set of either all neutral or all negatively arousing images)
Number of subjects: 84
Study 33261355 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed images
Number of subjects: 84
Study 33261355 — intervention group
Group type: COMPARATOR
Intervention: Pure images
Number of subjects: 84
Study 33261355 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fractal dimension from EEG
Number of subjects: 84
Study 35397138 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 250
Study 35397138 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 81 mg
Number of subjects: 250
Study 34290803 — intervention group
Group type: EXPERIMENTAL
Intervention: Maitland mobilization
Number of subjects: 30
Study 34290803 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study 32931708 — intervention group
Group type: EXPERIMENTAL
Intervention: bovine lactoferrin (bLF) 200 mg·(kg body mass)‐1·day‐1
Number of subjects: 335
Study 32931708 — intervention group
Group type: COMPARATOR
Intervention: maltodextrin (control)
Number of subjects: 335
Study 32931708 — intervention group
Group type: EXPERIMENTAL
Intervention: bovine lactoferrin (bLF)
Number of subjects: 335
Study 33031838 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 150
Study 35549708 — intervention group
Group type: COMPARATOR
Intervention: Sensor-Augmented Pump (SAP)
Number of subjects: 35
Study 35549708 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Zone Model Predictive Control AID
Number of subjects: 35
Study 34533579 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 0
Study 34533579 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir and Ritonavir
Number of subjects: 0
Study 34533579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32982204 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium/Olodaterol
Number of subjects: 80
Study 32982204 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 80
Study 35921506 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (0.75 mg twice daily, n = 100)
Number of subjects: 200
Study 35921506 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 100)
Number of subjects: 200
Study 33418951 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate, High Fat (LCHF) diet
Number of subjects: 14
Study 33418951 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate, High Fat (LCHF) diet after 2 days
Number of subjects: 14
Study 33418951 — intervention group
Group type: COMPARATOR
Intervention: High Carbohydrate (HC) diet
Number of subjects: 14
Study 35272649 — intervention group
Group type: EXPERIMENTAL
Intervention: Online education (1 face-to-face session + access to online education)
Number of subjects: 827
Study 35272649 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face education only (4 separate 1-h sessions)
Number of subjects: 827
Study 35272649 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 827
Study 33423364 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludora® Fusion 562.5 WP-SB (target dose 225 mg AI/m2)
Number of subjects: 0
Study 33423364 — intervention group
Group type: EXPERIMENTAL
Intervention: Clothianidin 70 WG (target dose 200 mg AI/m2)
Number of subjects: 0
Study 33423364 — intervention group
Group type: EXPERIMENTAL
Intervention: K-Othrine 250 WG (deltamethrin, target dose 25 mg AI/m2)
Number of subjects: 0
Study 33423364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ficam VC 80 WP-SB (bendiocarb, target dose 400 mg AI/m2)
Number of subjects: 0
Study 33423364 — intervention group
Group type: COMPARATOR
Intervention: Unsprayed control
Number of subjects: 0
Study 35291435 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin with vitamin E (20 mg atorvastatin and 400 IU vitamin E daily for 12 weeks)
Number of subjects: 30
Study 35291435 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin with placebo (20 mg atorvastatin daily for 12 weeks)
Number of subjects: 30
Study 35291435 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin with vitamin E
Number of subjects: 30
Study 32146550 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg three times daily (tds) in combination with carboplatin/paclitaxel
Number of subjects: 15
Study 32146550 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg tds
Number of subjects: 15
Study 34417416 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised group‐based multicomponent Otago Exercise Program (OEP)
Number of subjects: 111
Study 34417416 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised group‐based multicomponent exercise program intervention with oral nutritional supplementation (OEP+N)
Number of subjects: 111
Study 34417416 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 111
Study 33988924 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate once-monthly (PP1M)
Number of subjects: 275
Study 33988924 — intervention group
Group type: COMPARATOR
Intervention: Oral Antipsychotics (OAPs)
Number of subjects: 275
Study 32967638 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth support system as an addition to standard care
Number of subjects: 28
Study 32967638 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 28
Study 32716653 — intervention group
Group type: EXPERIMENTAL
Intervention: Online ratings from physician review websites (Healthgrades, Vitals)
Number of subjects: 100
Study 32716653 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient comments analysis
Number of subjects: 100
Study 32716653 — intervention group
Group type: COMPARATOR
Intervention: Comparison with CAHPS survey
Number of subjects: 100
Study 32894625 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard eradication triple therapy
Number of subjects: 80
Study 32894625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 35849455 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG 1.5 mg
Number of subjects: 70
Study 35849455 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG 3.0 mg
Number of subjects: 70
Study 35849455 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 70
Study 32081564 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative natural killer cell activity (NKA)
Number of subjects: 51
Study 32081564 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative NKA in patients with negative surgical margins
Number of subjects: 51
Study 32081564 — intervention group
Group type: EXPERIMENTAL
Intervention: NKA ratio (postoperative NKA/preoperative NKA) in patients with negative surgical margins
Number of subjects: 51
Study 32081564 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative NKA in lower-stage PCa
Number of subjects: 51
Study 35996355 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ESWT (n = 20)
Number of subjects: 40
Study 35996355 — intervention group
Group type: COMPARATOR
Intervention: Placebo ESWT (n = 20)
Number of subjects: 40
Study 32876805 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 117
Study 32876805 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine
Number of subjects: 117
Study 32643500 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard G-CSF administration (24 hours after chemotherapy)
Number of subjects: 21
Study 32643500 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed G-CSF administration (on the day ANC dropped below 1,000/mm3)
Number of subjects: 21
Study 32643500 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed G-CSF administration
Number of subjects: 21
Study 32643500 — intervention group
Group type: COMPARATOR
Intervention: Standard G-CSF administration
Number of subjects: 21
Study 34684661 — intervention group
Group type: EXPERIMENTAL
Intervention: OMEGA group (20 mL daily dose of dietary formula containing omega-3 and omega-6 PUFAs, vitamin A, vitamin E, and γ-tocopherol)
Number of subjects: 51
Study 34684661 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (20 mL placebo containing virgin olive oil)
Number of subjects: 51
Study 35882018 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic access by an optical trocar through the new point in the subxiphoid region (Group 1)
Number of subjects: 232
Study 35882018 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic access by an optical subumbilical trocar after Verres needle insufflation (Group 2)
Number of subjects: 232
Study 35882018 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 232
Study 35882018 — intervention group
Group type: COMPARATOR
Intervention: Group 2
Number of subjects: 232
Study 35843540 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat germ (40 g)
Number of subjects: 50
Study 35897098 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month multimodal weight maintenance intervention focusing on nutritional counseling and physical exercises
Number of subjects: 143
Study 35897098 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial weight loss
Number of subjects: 143
Study 35897098 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 143
Study 35897098 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight maintenance intervention
Number of subjects: 143
Study 33755508 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculation with strain Pap009 of Pseudomonas syringae pv. aptata (Psa)
Number of subjects: 24
Study 33755508 — intervention group
Group type: COMPARATOR
Intervention: Negative control with phosphate buffer and Carborundum
Number of subjects: 24
Study 32737004 — intervention group
Group type: EXPERIMENTAL
Intervention: NEXIRI (Irinotecan 120-180 mg/m2 intravenous on days 1 and 15 plus oral Sorafenib 400 mg twice a day)
Number of subjects: 173
Study 32737004 — intervention group
Group type: COMPARATOR
Intervention: IRI (Irinotecan 180 mg/m2)
Number of subjects: 173
Study 32737004 — intervention group
Group type: COMPARATOR
Intervention: NEX (Sorafenib only)
Number of subjects: 173
Study 33480852 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app-based intervention used for 28 days offering daily activities based on 10 recommendations to promote positive mental health.
Number of subjects: 152
Study 33480852 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app-based intervention
Number of subjects: 152
Study 33480852 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 152
Study 32555996 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 357
Study 32555996 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 357
Study 35218370 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg every 4 weeks
Number of subjects: 20
Study 35218370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 35218370 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 20
Study 34763441 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual injection of contrast (N group, n=50)
Number of subjects: 100